FDA
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals buys FDA priority review voucher for plozasiran
-
-
-
-
-
-
-
Arrowhead presents plozasiran data supporting use without dose adjustment
-
-
-
-
-
-
-
Arrowhead presents long-term plozasiran data for hypertriglyceridemia
-
-
-
-
-
-
-
Health Canada approves Arrowhead's REDEMPLO for rare triglyceride disorder
-
-
-
-
-
-
-
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
-
-
-
-
-
-
Arrowhead Pharma (ARWR) PT Lowered to $17 at Citi
-
330,179 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

